The so-called SDX Protocol, a roadmap prepared by directors, advisors and institutional investors to establish a play book for interaction between the investment community and independent corporate directors, was analyzed at the January 13 meeting of the National Association of … Continue reading
Category Archives: The Law
Did you ever get a thirst for an adult beverage during a snow storm, only to find your larder bare? Along comes Drizly, an application that can get your alcohol delivered to you, at least if you are in a … Continue reading
Proxy access, permitting shareholders to nominate directors and have that nomination included in the public company proxy statement itself, remains a volatile issue. You may recall that the SEC’s original regulation to provide shareholder access had two prongs: the first … Continue reading
During the time between year-end and the annual meeting, public boards are planning director elections, effecting audit review to conclude the annual financials, addressing 10K and proxy matters, evaluating shareholder proxy and other proposals from activists, and conducting intensified committee … Continue reading
If ever there was a company which tracks the history of start-ups from the late ‘90s to date, it is Bullhorn. Their highs and lows (they are a software solution for recruiting employees) were traced by Art Papas, CEO and … Continue reading
What are the trends in funding early stage life science companies? A panel of seven investors speculated on the 2015 outlook, at a December 10th Venture Summit held in Dedham yesterday. Riding an increasingly robust funding of transactions at the … Continue reading
Stock options are out, performance shares and restricted stock are in, equity may constitute 50% to 70% of the compensation of a public company CEO, and the ISS is on the move. Trends in CEO compensation for the coming year … Continue reading
Over the last few years, medical device companies have learned that in order to get financing at any level it is not only necessary to establish efficacy and potential economic benefits, but also necessary to understand a strategy for obtaining … Continue reading
At the November 7th MassMEDIC Boston conference on medical devices, a panel suggested that the medical device industry could learn a lot about how to finance early stage development by looking at the bio pharma model. It was posited that … Continue reading
At the MassMEDIC conference in Boston last Friday, Neil Oboroi of BOA/Merrill Lynch, an investment banker based in New York, discussed the M&A market for healthcare in general and medical devices in particular. As befits an investment banker, he was enthused with … Continue reading